Skip to main content
main-content

The independent medical news service

15-12-2017 | HBV | News | Article

HBV remains major contributor to primary liver cancer globally

Hepatitis B virus infection is the leading cause of incident primary liver cancer and associated mortality worldwide, according to research published in JAMA Oncology.

11-12-2017 | HBV | News | Article

Partial TDF responders achieve virologic response with treatment continuation

Most patients with chronic hepatitis B virus infection initially classed as partial responders to treatment with tenofovir disoproxil fumarate achieve a virologic response without additional treatment adjustment, research suggests.

11-12-2017 | HBV | News | Article

HCC, mortality risk remains for untreated immune tolerant-phase HBV patients

Being in the immune tolerant phase of chronic hepatitis B virus (HBV) infection is no assurance against the risk for developing hepatocellular carcinoma (HCC), requiring liver transplantation, or dying, say South Korean investigators.

23-11-2017 | Gastrointestinal cancer | News | Article

Anal cancer burden high among people with HIV

People with HIV infection are nearly 20 times more like to develop anal cancer than those in the general population, study findings indicate.

29-09-2017 | HBV | News | Article

Consensus reached on design of clinical trials for novel, curative HBV therapies

A panel of hepatitis B virus experts has issued a consensus statement intended to aid in standardizing the efficacy and safety appraisals of novel, potentially curative antiviral and immune modulatory agents.

29-09-2017 | HBV | News | Article

Novel indices to diagnose fibrosis in chronic HBV patients developed

Two research groups have developed noninvasive indices to detect significant fibrosis in treatment-naïve patients with chronic hepatitis B virus infection, one using serum levels of Golgi protein 73 and liver stiffness, and the other based on the ratio of gamma-glutamyl transpeptidase to albumin.

26-09-2017 | HBV | News | Article

Sex modifies age-related HCC risk after HBsAg clearance

Achieving hepatitis B surface antigen seroclearance neutralizes the increased risk for hepatitis B virus-related hepatocellular carcinoma among women aged 50 years or younger, but not among older women or men regardless of their age, research indicates.

26-09-2017 | HBV | News | Article

Treatment-induced liver stiffness reduction lowers HCC risk in HBV patients

Achieving a subcirrhotic liver stiffness level after antiviral therapy halves the risk for hepatocellular carcinoma in patients with chronic hepatitis B virus-related advanced fibrosis or cirrhosis, Korean research shows.

22-09-2017 | HBV | News | Article

Perinatal HBV infection ‘nearly eliminated’ with Japan’s selective vaccination program

The Japanese nationwide selective vaccination strategy has led to a substantial reduction in perinatal hepatitis B virus transmission, say researchers who evaluated the prevalence of hepatitis B surface antigen among pregnant women born before and after its implementation.

22-09-2017 | HBV | News | Article

High metabolic risk burden increases HCC risk in HBV patients

A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.

07-09-2017 | Rheumatology | News | Article

Vaccination, monotherapy could reduce herpes zoster risk in tofacitinib-treated RA patients

Two studies published in Arthritis & Rheumatology explore strategies for reducing herpes zoster risk among patients with rheumatoid arthritis treated with the Janus kinase inhibitor tofacitinib.

06-09-2017 | Rheumatology | News | Article

Neutrophil-to-lymphocyte ratio may aid infection diagnosis in SLE

The ratio of absolute neutrophil to lymphocyte count could be an effective additional biomarker for detecting infection in patients with systemic lupus erythematosus, research suggests.

15-08-2017 | HBV | News | Article

Serum biomarkers combine to improve HCC risk stratification in HBV patients with low viremia

In patients with persistently low serum levels of hepatitis B virus DNA, the combined use of the noninvasive aspartate aminotransferase to platelet ratio index and the Fibrosis-4 index could help identify those at increased risk for developing hepatocellular carcinoma.

15-08-2017 | HBV | News | Article

HCC incidence declines with prolonged HBV treatment

The incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection declines significantly after the first 5 years of treatment with the nucleos(t)ide analogs entecavir and/or tenofovir, researchers report.

11-08-2017 | HBV | News | Article

Real-world outcomes of antiviral therapy in Asian chronic HBV patients described

Analysis of a community-based cohort comprising mainly Asian patients receiving antiviral therapy for chronic hepatitis B virus infection shows a higher rate of hepatitis B surface antigen loss than is generally reported for Asian clinical trial cohorts.

04-08-2017 | HBV | News | Article

Anti-HBc levels predict hepatic inflammation in patients with chronic HBV

Serum hepatitis B core antibody levels significantly predict hepatic inflammation in patients with chronic hepatitis B virus infection, including those with normal alanine aminotransferase levels, Chinese research shows.

27-07-2017 | HBV | News | Article

Maternal HBV infection raises preterm birth risk

Women with hepatitis B virus infection prior to becoming pregnant are significantly more likely to have a preterm birth than those without HBV, shows an analysis of a Chinese population-based cohort.

27-07-2017 | HBV | News | Article

Temporal liver cancer trends in HBV-endemic population mapped

A South Korean population-based study shows an increase in liver cancer burden over a 14-year period, while another analysis in the same population shows an improvement in the survival of patients with hepatocellular cancer in the past decade.

05-06-2017 | HBV | News | Article

Overt, occult HBV infection remains a concern despite immunization

Despite a universal program to vaccinate newborns against hepatitis B virus infection, the prevalence of overt and occult infection among children in northwest China is a cause for concern, say researchers.

05-06-2017 | HBV | News | Article

Support for TDF in patients with HBV-related decompensated cirrhosis

Among patients with hepatitis B virus-related decompensated cirrhosis, first-line tenofovir disoproxil fumarate therapy not only reduces HBV DNA levels, but also improves hepatic function, indicates a real-world South Korean study.

Image Credits